Bioxytran, Inc. · OTC:BIXT

Bioxytran — Investor Presentation (January 2022)

35 slides from Bioxytran's investor presentation, Jan 14, 2022

Slide 2: Forward Looking Statement
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Forward Looking Statement This Descriptive Presentation (the “Presentation") has been prepared by Bioxytran, Inc (the “Company”) and recipients are not entitled to rely on the accuracy or completeness of the Presentation . Statistical informati
Slide 3: Mission Statement
Copyright © Bioxytran 2022. All rights. Version 2.01.01 3 Mission Statement Bioxytran is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design
Slide 4: Technology Overview
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Virology: • Covid - 19 • Influenza • Other virologic diseases Long term symptoms resulting from viral infections (long - hauler): • ARDS • Pulmonary Fibrosis Technology Overview ProLectin Rx – Glycovirology BXT - 25 – Hypoxia & Degenerative Dis
Slide 6: Lingering Effects of COVID-19
Copyright © Bioxytran 2022. All rights. Version 2.01.01 New mutations Alpha, Delta, Omicron, ? Variants are complicating the vaccination strategy If herd immunity is unattainable Therapeutic treatments are the ONLY fall back position 80% Herd Immunity 80% level has not been reached World Population
Slide 7: ProLectin-Rx Galectin Antagonists
Copyright © Bioxytran 2022. All rights. Version 2.01.01 ProLectin - Rx Galectin Antagonists First line of defense against all mutations of Covid - 19 STATUS: SWIFT approval pathway - Phase 3 Ready Universal Universal pandemic therapeutic Tested Complete elimination of mild to moderate cases (phase I
Slide 8: Treatment
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Treatment ProLectin - M Oral ProLectin - I Intravenous ProLectin - A Intravenous ProLectin - F Intravenous Combination MDX - Viewer End - to - End Solution Stage IV (long hauler) Fibrosis Elevated Galectin - 3 ~20 days ARDS Viral response 8
Slide 9: Viral Load vs. Time, ProLectin-M Treated Patients
Copyright © Bioxytran 2022. All rights. Version 2.01.01 9 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 3 5 7 Viral Load (Log10(average(N1+N2) Copies/mL)) Time (days) Viral Load Vs. Time ProLectin - M Treated Patients PL-CIM-002 PL-CIM-004 PL-CIM-005 PL-CIM-008 PL-CIM-009 1 Galectin Antagonist use in Mild
Slide 10: Viral Curve Comparison
Copyright © Bioxytran 2022. All rights. Version 2.01.01 10 Viral Curve Comparison 1 A quantitative model used to compare within - host SARS - CoV - 2, MERS - CoV, and SARS - CoV dynamics provides insights into the pathogen esis and treatment of SARS - CoV - 2 (plos.org) 2 Galectin Antagonist use in
Slide 11: ProLectin-M Treatment Results in Spike Protein Specific Antibody Immunity
Copyright © Bioxytran 2022. All rights. Version 2.01.01 ProLectin - M Treatment Results in SARS - CoV - 2 Spike Protein Specific Antibody Immunity Introducing Post Infection Immunization ProLectin – M clears the blood of viral load thereby reducing the strain on the Innate immune system so the Adapt
Slide 12: Galectin Inhibitor Tags Virus For Elimination
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Galectin Inhibitor Tags Virus For Elimination Copyright © Bioxytran 2022. All rights. 12 Theoretical Mechanism of Action Liver Filtration Galectin Inhibitor Virus Human Cells Version 2.01.01
Slide 13: Clinical Research
Copyright © Bioxytran 2022. All rights. Version 2.01.01 https:// www.longdom.org /abstract/galectin - antagonist - use - in - mild - cases - of - sarscov2 - pilot - feasibility - randomised - open - label - controlled - trial - 61087.html Clinical Research 13 Version 2.01.01
Slide 14: Proposed Phase 3 Clinical Trial Design
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Proposed Phase 3 Clinical Trial Design Phase 3 Clinical Trial • 408 participants • Double Blind Randomized Controlled Trial (DBRCT) • Change in seropositivity at day 14 • Broad inclusion criteria (Vaccination status irrelevant) 14 Version 2.01.
Slide 15: Glycovirology Development Pipeline
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Product Indication Discovery Preclinical Phase I Phase II Phase III Phase IV ProLectin - M Oral Virology – Mild to Moderate • Covid - 19 • Influenza • Other virologic diseases ProLectin - I Intravenous Virology – Severe cases • Covid - 19 • Inf
Slide 16: Therapeutic Approaches for COVID-19
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Vaccines Immunomodulatory Oxygenation (Ventilators) Regenerative Medicine (Stemcells) ProLectin - Rx □ Unique Galectin Antagonist – Oral/IV Polysaccharide □ It’s not a vaccine, nor an antiretroviral drug Antiretrovirals ( Compete for polymorphi
Slide 17: Competitive Landscape
Copyright © Bioxytran 2022. All rights. Version 2.01.01 17 Competitive Landscape Oral COVID - 19 Therapeutics Drug Company Description Gov. Award Clinical stage Molnupiravir Merck Mutagenesis via RdRp – forced mutations induced apoptosis $2.2 billion EUA Paxlovid Pfizer 3CL protease inhibitor – Anti
Slide 18: BXT-25 Hypoxia & Degenerative Diseases
BXT - 25 – Hypoxia & Degenerative Diseases 18 18 Version 2.01.01
Slide 19: The Brain Stroke Epidemic
Copyright © Bioxytran 2022. All rights. Version 2.01.01 The Brain Stroke Epidemic A Challenge to Worldwide Healthcare, a $500 Billion Medical Indication Costs 19 Region Strokes Population Survivors Direct cost Indirect cost US 0.8 million 330 million 5.8 million $44 billion $22 billion EU (+GB) 1.1
Slide 20: The Golden Hour Dilemma
Copyright © Bioxytran 2022. All rights. Version 2.01.01 The Golden Hour Dilemma 20 Time to Needle 2.5 hours Equivalent to 9 Years of Aging* Onset of symptoms Ambulance arrives at home Arrival and initial assessment and treatment in ER Thombolysis or PTCA/CABG Blockage Removed * Time Is Brain — Quant
Slide 21: Solution: BXT-25 an Oxygen Bridge
Copyright © Bioxytran 2022. All rights. Version 2.01.01 21 Solution: BXT - 25 an Oxygen Bridge • BXT - 25 is a hemoglobin - based polymer; 5,000 times smaller than a red blood cell • It can be used both in Ischemic and Hemorrhagic Stroke • It can penetrate a blood - clot and reach the brain within 3
Slide 22: How It Works? BXT-25 Stabilized Oxygen-carrying Protein
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Copyright © Bioxytran 2022. All rights. Version 2.01.01 22 How It Works? BXT - 25 – Stabilized Oxygen - carrying Protein Erythrocyte Hemoglobin Heme Single O 2 molecule • Delivered as an IV solution • Universally compatible with all blood types
Slide 23: Proprietary Manufacturing Process of BXT-25
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Proprietary Manufacturing Process of BXT - 25 Collect controlled source Red blood cells Extract Hemoglobin Protein Purify and crosslink Extract Heme and reattach to a polymer BXT - 25 is mixed with a saline solution, to be IV - infused by an ER
Slide 24: Proof of Concept of BXT-25 in Animals
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Proof of Concept of BXT - 25 in Animals Middle Cerebral Artery Blockage Model in Rats 24 Hypoxic area Absence of nitric oxide scavenging, no increased blood pressure in diabetic mice (Harvard Medical School, 2013) No toxicity from replacing 90%
Slide 25: Limited Effective Treatment Options
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Limited Effective Treatment Options Our competition is tPA and similar drugs, aiming to dissolve, or remove, a clot. These are time - consuming and require an MRI since blood - thinners are fatal in hemorrhagic strokes. THERE ARE NO DRUGS AVAIL
Slide 27: FDA Approved Companion Diagnostics OXYSENSE
Copyright © Bioxytran 2022. All rights. Version 2.01.01 FDA Approved Companion Diagnostics OXYSENSE - A clinical end - point for measuring oxygen delivery to the brain in real - time Flat probe Treated Aneurysm Tissue/brain monitored parameters Mitochondrial NADH (ATP) Hb Saturation (O 2 ) Cerebral
Slide 28: Degenerative Disease/Hypoxia Development Pipeline
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Degenerative Disease/Hypoxia Development Pipeline Treatment/Device Indication Discovery Preclinical Phase I Phase II Phase III Phase IV BXT - 101 Cancer Metastasis BXT - 102 NASH • Cirrhosis • Fibrosis BXT - 251+ Oxysense Organ Transplantation
Slide 29: Business Development & Strategy
Business Development & Strategy 29 29 Version 2.01.01
Slide 30: Clinical Trial Strategy
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Clinical Trial Strategy 2021 2022 Product Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 ProLectin - M ProLectin - I ProLectin - F ProLectin - A / BXT - 25 Phase I/II Pre - clinical Development Phase I/II Phase III 30 Pre - clinical Development Pre - clinical Develop
Slide 31: Business Strategy
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Business Strategy Business Development Strategy • Collaboration agreement with qualified partner’s • Out - license agreements with Big Pharma Intellectual Property (IP) • One issued US patent (US6245316B1) • Two international patents pending ap
Slide 32: Potential Big Pharma Partners
Copyright © Bioxytran 2022. All rights. Version 2.01.01 • Johnson & Johnson – Oncology, Neuroscience, Immunology, Cardiovascular, Vaccines, HIV • Roche Holdings – Oncology, Neuroscience, Immunology, Hematology, Ophthalmology • Pfizer – Oncology, Neuroscience, Cardiovascular, Diabetes • Novartis – On
Slide 33: Use of Proceeds
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Use of Proceeds Current Round – S - 1 ProLectin - M ProLectin - I ProLectin - F ProLectin - Rx* Estimated Project Cost in thousands USD* $ 2,700 $ 1,650 $ 1,000 $ 5,350 Development & GLP - - - - Pre - Clinical 100 150 150 400 IND Submission 150
Slide 34: Management
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Management David Platt PhD, CEO, CSO, Chairman Carbohydrate chemistry expert, founded four publicly traded companies, raised $150m in public markets, created $1B in shareholder value, and led development of two drugs. Ola Soderquist CPA, MSA, M
Slide 35: Contact
Copyright © Bioxytran 2022. All rights. Version 2.01.01 Copyright © Bioxytran 2021. All rights. Bioxytran, Inc. 75 2 nd Ave., Suite 605 Needham MA, 02494 (617) - 454 - 1199 www.bioxytraninc.com info@bioxytraninc.com Mike Sheikh mike.sheikh@bioxytraninc.com (509) - 991 - 0245 Version 2.01.01

Bioxytran — Investor Presentation (January 2022) on 6ix

Bioxytran — Investor Presentation (January 2022)

Slide 1: Corporate Overview

Slide 2: Forward Looking Statement

Slide 3: Mission Statement

Slide 4: Technology Overview

Slide 5: ProLectin Rx Glycovirology

Slide 6: Lingering Effects of COVID-19

Slide 7: ProLectin-Rx Galectin Antagonists

Slide 8: Treatment

Slide 9: Viral Load vs. Time, ProLectin-M Treated Patients

Slide 10: Viral Curve Comparison

Slide 11: ProLectin-M Treatment Results in Spike Protein Specific Antibody Immunity

Slide 12: Galectin Inhibitor Tags Virus For Elimination

Slide 13: Clinical Research

Slide 14: Proposed Phase 3 Clinical Trial Design

Slide 15: Glycovirology Development Pipeline

Slide 16: Therapeutic Approaches for COVID-19

Slide 17: Competitive Landscape

Slide 18: BXT-25 Hypoxia & Degenerative Diseases

Slide 19: The Brain Stroke Epidemic

Slide 20: The Golden Hour Dilemma

Slide 21: Solution: BXT-25 an Oxygen Bridge

Slide 22: How It Works? BXT-25 Stabilized Oxygen-carrying Protein

Slide 23: Proprietary Manufacturing Process of BXT-25

Slide 24: Proof of Concept of BXT-25 in Animals

Slide 25: Limited Effective Treatment Options

Slide 26: How Do We Measure Tissue Oxygen Level?

Slide 27: FDA Approved Companion Diagnostics OXYSENSE

Slide 28: Degenerative Disease/Hypoxia Development Pipeline

Slide 29: Business Development & Strategy

Slide 30: Clinical Trial Strategy

Slide 31: Business Strategy

Slide 32: Potential Big Pharma Partners

Slide 33: Use of Proceeds

Slide 34: Management

Slide 35: Contact